Jubilant Therapeutics' JBI-778 IND application receives US FDA approval to treat solid tumours with brain metastases and primary brain tumours.

M2 EQUITYBITES-August 4, 2022-Jubilant Therapeutics' JBI-778 IND application receives US FDA approval to treat solid tumours with brain metastases and primary brain tumours

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Jubilant Therapeutics Inc., a US-based biopharmaceutical company, announced on Wednesday that it has received approval from United States Food and Drug Administration (US FDA) for the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, intended to treat solid tumours with brain metastases and primary brain tumours including high-grade glioma.

The Phase I/II trial is an open-label, two-part dose escalation and expansion study, aimed at defining the product's safety profile, pharmacokinetics, optimal dosing and preliminary activity. The participants in the dose...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT